Narcolepsy and Other Central Hypersomnias

Area of Science:

• Sleep Medicine
• Neurology
• Clinical Pathophysiology

Background:

• Central disorders of hypersomnolence, including narcolepsy types 1 and 2, idiopathic hypersomnia, and Kleine-Levin syndrome, are defined in the International Classification of Sleep Disorders, Third Edition (ICSD-3).
• Recent updates in ICSD-3 rename narcolepsy with cataplexy to narcolepsy type 1 and narcolepsy without cataplexy to narcolepsy type 2.

Observation:

• A low level of hypocretin-1/orexin-A in cerebrospinal fluid (CSF) is a highly specific and sensitive biomarker for diagnosing narcolepsy type 1.
• Other central hypersomnias remain less defined, with variable phenotypes and limited reliable biomarkers.
• Influenza A (H1N1) infection and vaccination are identified as potential triggers for narcolepsy type 1, suggesting an autoimmune process targeting hypocretin neurons.

Findings:

• Treatment for narcolepsy is primarily symptomatic, utilizing agents like modafinil, armodafinil, methylphenidate, or amphetamines.
• Newer treatments include sodium oxybate for cataplexy and wakefulness, and pitolisant, a histamine H3 receptor inverse agonist.
• Understanding the autoimmune mechanisms behind hypocretin neuron destruction in narcolepsy type 1 is an active area of research.

Implications:

• Central hypersomnias are severe and disabling sleep disorders, despite their lower prevalence compared to other sleep conditions.
• Early recognition and diagnosis are critical for optimizing patient quality of life and daily functioning, particularly in pediatric cases.
• Advances in understanding pathophysiology and developing targeted treatments offer hope for improved management of these debilitating conditions.